Explore more publications!

Press Releases

GCL Announces $3 Million Strategic Investment in Publishing Subsidiary, 4Divinity, by ADATA Technology
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference
Toobit Clinches Dual Victory at Blockchain Life Awards 2025
GCL Announces Fiscal Year 2026 Revenue and Gross Profit Expectations
Charlie Rothkopf Sets New Standard for Leadership Grounded in Integrity, Transparency, and Innovation
DFPI Fines Crypto Lending Platform, Nexo Capital Inc., $500,000 in Penalties

DFPI Fines Crypto Lending Platform, Nexo Capital Inc., $500,000 in Penalties

CZR Exchange Establishes Core Brand Principles Rooted in Integrity, Transparency, and Relentless Innovation
EntravelX Joins Chainlink & Solana's BUILD Program to Accelerate AI-Powered, Crypto-Native Travel Infrastructure
Toobit Kicks Off $100,000 Event Contracts Campaign with Guaranteed Loss Protection
Consolidated Water Sets Third Quarter 2025 Investor Conference Call for Tuesday, November 11, 2025 at 11:00 a.m. ET
Responses to the SEC’s Concept Release on Foreign Private Issuer Eligibility

Responses to the SEC’s Concept Release on Foreign Private Issuer Eligibility

Greenlight Capital Re, Ltd. Schedules Third Quarter 2025 Financial Results and Conference Call
EBC Financial Group Launches World’s First Trading Initiative to Protect the Amazon with Every Trade
Toobit Launches AI vs Lead Traders Showdown with 130,000 USDT Prize Pool
EBC Financial Group Highlights Digital Payments Growth Reshaping South Africa’s Economy
Remarks by Chair Atkins at the Investor Advisory Committee Meeting

Remarks by Chair Atkins at the Investor Advisory Committee Meeting

CYPFER Weighs in on AI Governance at the United Nations Global Dialogue
EHang Reports Third Quarter 2025 Unaudited Financial Results
Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions